EXE Stock Analysis: Extendicare | TO
Medical Care Facilities | TO, Canada | Market Cap: 2.593m CAD | 12M Return: 66.3% | CA30224T8639 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 13.5M
EPS Trend: 57.6%
Rev. Trend: 96.4%
Qual. Beats: 2
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.8 years of data, until 10/2026
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, ≥40 worth a closer look and ≥60 is strong.
Extendicare Inc. provides senior care services across Canada through its Long-term Care, Home Health Care, and Managed Services segments. Its offerings include residential care and daily living support, in-home nursing and therapy, and management and consulting services for third parties and joint ventures.
The company operates under brands including Extendicare and ParaMed. Its mix of residential and home-based services reflects two common parts of the health care facilities sector: care in dedicated residences and support delivered in people’s homes.
- Government funding and occupancy drive long-term care revenue growth
- Wage inflation pressures margins across care operations
- Revera home acquisition expands capacity and operating scale
| Net Income: 121.3m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.04 > 0.02 and ΔFCF/TA -6.35 > 1.0 |
| NWC/Revenue: -4.78% < 20% (prev -3.21%; Δ -1.56% < -1%) |
| CFO/TA 0.10 > 3% & CFO 149.5m > Net Income 121.3m |
| Net Debt (552.3m) to EBITDA (213.4m): 2.59 < 3 |
| Current Ratio: 0.75 > 1.5 & < 3 |
| Outstanding Shares: last quarter (96.7m) vs 12m ago 12.98% < -2% |
| Gross Margin: 26.17% > 18% (prev 12.13%; Δ 14.04% > 0.5%) |
| Asset Turnover: 169.5% > 50% (prev 194.0%; Δ -24.43% > 0%) |
| Interest Coverage Ratio: 7.01 > 6 (EBIT TTM 166.9m / Interest Expense TTM 23.8m) |
| A: -0.06 (Total Current Assets 289.6m - Total Current Liabilities 384.1m) / Total Assets 1.56b |
| B: -0.17 (Retained Earnings -264.9m / Total Assets 1.56b) |
| C: 0.14 (EBIT TTM 166.9m / Avg Total Assets 1.17b) |
| D: 0.35 (Book Value of Equity 404.8m / Total Liabilities 1.15b) |
| Altman-Z'' = 0.38 = B |
| DSRI: 1.25 (Receivables 159.1m/96.8m, Revenue 1.98b/1.51b) |
| GMI: 0.46 (GM 12.13% / 26.17%) |
| AQI: 2.53 (AQ_t 0.58 / AQ_t-1 0.23) |
| SGI: 1.31 (Revenue 1.98b / 1.51b) |
| TATA: -0.02 (NI 121.3m - CFO 149.5m) / TA 1.56b) |
| Beneish M = -2.18 (Cap -4..+1) = BB |
As of November 13, 2026, the stock is trading at CAD 30.09 with a total of 562,715 shares traded. Over the past week, the price has changed by +10.30%, over one month by +13.09%, over three months by -5.78% and over the past year by +66.30%.
Current recommended Stop Loss: 28.80 (which is 4.3% or 1.2 ATR below the current price).
Extendicare has no consensus analysts rating.
P/E Trailing = 20.5113
P/E Forward = 18.3824
P/S = 1.3105
P/B = 6.643
Revenue TTM = 1.98b CAD
EBIT TTM = 166.9m CAD
EBITDA TTM = 213.4m CAD
Long Term Debt = 634.7m CAD (from longTermDebt, last quarter)
Short Term Debt = 11.0m CAD (from shortTermDebt, last quarter)
Debt = 645.7m CAD (from shortLongTermDebtTotal, last quarter)
Net Debt = 552.3m CAD (calculated: Debt 645.7m - CCE 93.5m)
Enterprise Value = 3.15b CAD (2.59b + Debt 645.7m - CCE 93.5m)
Interest Coverage Ratio = 7.01 (Ebit TTM 166.9m / Interest Expense TTM 23.8m)
EV/FCF = 53.21x (Enterprise Value 3.15b / FCF TTM 59.1m)
FCF Yield = 1.88% (FCF TTM 59.1m / Enterprise Value 3.15b)
FCF Margin = 2.99% (FCF TTM 59.1m / Revenue TTM 1.98b)
Net Margin = 6.13% (Net Income TTM 121.3m / Revenue TTM 1.98b)
Gross Margin = 26.17% ((Revenue TTM 1.98b - Cost of Revenue TTM 1.46b) / Revenue TTM)
Gross Margin QoQ = none% (prev 12.65%)
Tobins Q-Ratio = 2.02 (Enterprise Value 3.15b / Total Assets 1.56b)
Interest Expense / Debt = 3.69% (Interest Expense 23.8m / Debt 645.7m)
Taxrate = 22.83% (35.9m / 157.2m)
NOPAT = 128.8m (EBIT 166.9m * (1 - 22.83%))
Current Ratio = 0.75 (Total Current Assets 289.6m / Total Current Liabilities 384.1m)
Debt / Equity = 1.60 (Debt 645.7m / totalStockholderEquity, last quarter 404.8m)
Debt / EBITDA = 2.59 (Net Debt 552.3m / EBITDA 213.4m)
Debt / FCF = 9.34 (Net Debt 552.3m / FCF TTM 59.1m)
Total Stockholder Equity = 333.8m (last 4 quarters mean from totalStockholderEquity)
RoA = 10.39% (Net Income 121.3m / Total Assets 1.56b)
RoE = 36.33% (Net Income TTM 121.3m / Total Stockholder Equity 333.8m)
RoCE = 17.24% (EBIT 166.9m / Capital Employed (Equity 333.8m + L.T.Debt 634.7m))
RoIC = 11.82% (NOPAT 128.8m / Invested Capital 1.09b)
WACC = 4.95% (E(2.59b)/V(3.24b) * Re(5.48%) + D(645.7m)/V(3.24b) * Rd(3.69%) * (1-Tc(0.23)))
Discount Rate = 5.48% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 6.28 | Cagr: 0.73%
[DCF] Terminal Value 73.10% ; FCFF base≈67.0m ; Y1≈58.8m ; Y5≈47.5m
[DCF] Fair Price = 2.21 (EV 762.4m - Net Debt 552.3m = Equity 210.1m / Shares 95.0m; r=8.35% [WACC [floored]]; 5y FCF grow -15.0% → 2.50% )
EPS Correlation: 57.64 | EPS CAGR: 74.09% | SUE: N/A | # QB: 0
Revenue Correlation: 96.40 | Revenue CAGR: 14.82% | SUE: 2.76 | # QB: 2
EPS current Quarter (2026-09-30): EPS=0.36 | Chg30d=-7.18% | Revisions=-25% | Analysts=1
EPS current Year (2026-12-31): EPS=1.45 | Chg30d=-4.61% | Revisions=-17% | GrowthEPS=+30.3% | GrowthRev=+39.0%
EPS next Year (2027-12-31): EPS=1.62 | Chg30d=+0.95% | Revisions=+29% | GrowthEPS=+12.0% | GrowthRev=+10.1%
[Analyst] Revisions Ratio: +0% (up=4, down=4)